A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: A Children's Oncology Group Phase I Consortium report

Brigitte C. Widemann, AeRang Kim, Elizabeth Fox, Sylvain Baruchel, Peter C. Adamson, Ashish M. Ingle, Julia Glade Bender, Michael Burke, Brenda Weigel, Diana Stempak, Frank M. Balis, Susan M. Blaney

Research output: Contribution to journalArticle

Abstract

Purpose: To determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of sorafenib in children with refractory extracranial solid tumors and evaluate the tolerability of the solid tumor MTD in children with refractory leukemias. Experimental Design: Sorafenib was administered orally every 12 hours for consecutive 28-day cycles. Pharmacokinetics (day 1 and steady-state) and pharmacodynamics were conducted during cycle 1. Results: Of 65 patients enrolled, 60 were eligible. In the solid tumor cohort (n = 49), 4 of 6 patients experienced a DLT [hypertension, pain, rash/urticaria, thrombocytopenia, alanine aminotransferase (ALT)/aspartate aminotransferase (AST)] at the starting dose (150 mg/m2/dose) which resulted in de-escalation to 105 mg/m2/dose. After eligibility criteria modification and dose re-escalation, the MTD was 200 mg/m 2/dose for solid tumors and 150 mg/m2/dose for leukemias. Sorafenib exposure was highly variable between patients but was within the ranges reported in adults. The apparent sorafenib clearance increased with patient age. Diarrhea, rash, fatigue, and increased ALT/AST were the most common sorafenib-related toxicities. Stable disease for 4 or more cycles was observed in 14 solid tumor patients, and 2 patients with acute myeloid leukemia (AML) and FLT3 internal tandem duplication (FLT3ITD) experienced a decrease in bone marrow blasts to less than 5%. Conclusions: The recommended phase II dose of sorafenib administered every 12 hours continuously for children with solid tumors is 200 mg/m2/dose and 150 mg/m2/dose for children with leukemias. Sorafenib toxicities and distribution in children are similar to adults. The activity of sorafenib in children with AML and FLT3ITD is currently being evaluated, and a phase II study for select solid tumors is ongoing.

Original languageEnglish (US)
Pages (from-to)6011-6022
Number of pages12
JournalClinical Cancer Research
Volume18
Issue number21
DOIs
StatePublished - Nov 1 2012
Externally publishedYes

Fingerprint

Leukemia
Pharmacokinetics
Maximum Tolerated Dose
Neoplasms
Aspartate Aminotransferases
Exanthema
Alanine Transaminase
Acute Myeloid Leukemia
sorafenib
Urticaria
Thrombocytopenia
Fatigue
Diarrhea
Research Design
Bone Marrow
Hypertension
Pain

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias : A Children's Oncology Group Phase I Consortium report. / Widemann, Brigitte C.; Kim, AeRang; Fox, Elizabeth; Baruchel, Sylvain; Adamson, Peter C.; Ingle, Ashish M.; Bender, Julia Glade; Burke, Michael; Weigel, Brenda; Stempak, Diana; Balis, Frank M.; Blaney, Susan M.

In: Clinical Cancer Research, Vol. 18, No. 21, 01.11.2012, p. 6011-6022.

Research output: Contribution to journalArticle

Widemann, BC, Kim, A, Fox, E, Baruchel, S, Adamson, PC, Ingle, AM, Bender, JG, Burke, M, Weigel, B, Stempak, D, Balis, FM & Blaney, SM 2012, 'A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: A Children's Oncology Group Phase I Consortium report', Clinical Cancer Research, vol. 18, no. 21, pp. 6011-6022. https://doi.org/10.1158/1078-0432.CCR-11-3284
Widemann, Brigitte C. ; Kim, AeRang ; Fox, Elizabeth ; Baruchel, Sylvain ; Adamson, Peter C. ; Ingle, Ashish M. ; Bender, Julia Glade ; Burke, Michael ; Weigel, Brenda ; Stempak, Diana ; Balis, Frank M. ; Blaney, Susan M. / A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias : A Children's Oncology Group Phase I Consortium report. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 21. pp. 6011-6022.
@article{efb476f39868455fba87bfc0a125a6aa,
title = "A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: A Children's Oncology Group Phase I Consortium report",
abstract = "Purpose: To determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of sorafenib in children with refractory extracranial solid tumors and evaluate the tolerability of the solid tumor MTD in children with refractory leukemias. Experimental Design: Sorafenib was administered orally every 12 hours for consecutive 28-day cycles. Pharmacokinetics (day 1 and steady-state) and pharmacodynamics were conducted during cycle 1. Results: Of 65 patients enrolled, 60 were eligible. In the solid tumor cohort (n = 49), 4 of 6 patients experienced a DLT [hypertension, pain, rash/urticaria, thrombocytopenia, alanine aminotransferase (ALT)/aspartate aminotransferase (AST)] at the starting dose (150 mg/m2/dose) which resulted in de-escalation to 105 mg/m2/dose. After eligibility criteria modification and dose re-escalation, the MTD was 200 mg/m 2/dose for solid tumors and 150 mg/m2/dose for leukemias. Sorafenib exposure was highly variable between patients but was within the ranges reported in adults. The apparent sorafenib clearance increased with patient age. Diarrhea, rash, fatigue, and increased ALT/AST were the most common sorafenib-related toxicities. Stable disease for 4 or more cycles was observed in 14 solid tumor patients, and 2 patients with acute myeloid leukemia (AML) and FLT3 internal tandem duplication (FLT3ITD) experienced a decrease in bone marrow blasts to less than 5{\%}. Conclusions: The recommended phase II dose of sorafenib administered every 12 hours continuously for children with solid tumors is 200 mg/m2/dose and 150 mg/m2/dose for children with leukemias. Sorafenib toxicities and distribution in children are similar to adults. The activity of sorafenib in children with AML and FLT3ITD is currently being evaluated, and a phase II study for select solid tumors is ongoing.",
author = "Widemann, {Brigitte C.} and AeRang Kim and Elizabeth Fox and Sylvain Baruchel and Adamson, {Peter C.} and Ingle, {Ashish M.} and Bender, {Julia Glade} and Michael Burke and Brenda Weigel and Diana Stempak and Balis, {Frank M.} and Blaney, {Susan M.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1158/1078-0432.CCR-11-3284",
language = "English (US)",
volume = "18",
pages = "6011--6022",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias

T2 - A Children's Oncology Group Phase I Consortium report

AU - Widemann, Brigitte C.

AU - Kim, AeRang

AU - Fox, Elizabeth

AU - Baruchel, Sylvain

AU - Adamson, Peter C.

AU - Ingle, Ashish M.

AU - Bender, Julia Glade

AU - Burke, Michael

AU - Weigel, Brenda

AU - Stempak, Diana

AU - Balis, Frank M.

AU - Blaney, Susan M.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Purpose: To determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of sorafenib in children with refractory extracranial solid tumors and evaluate the tolerability of the solid tumor MTD in children with refractory leukemias. Experimental Design: Sorafenib was administered orally every 12 hours for consecutive 28-day cycles. Pharmacokinetics (day 1 and steady-state) and pharmacodynamics were conducted during cycle 1. Results: Of 65 patients enrolled, 60 were eligible. In the solid tumor cohort (n = 49), 4 of 6 patients experienced a DLT [hypertension, pain, rash/urticaria, thrombocytopenia, alanine aminotransferase (ALT)/aspartate aminotransferase (AST)] at the starting dose (150 mg/m2/dose) which resulted in de-escalation to 105 mg/m2/dose. After eligibility criteria modification and dose re-escalation, the MTD was 200 mg/m 2/dose for solid tumors and 150 mg/m2/dose for leukemias. Sorafenib exposure was highly variable between patients but was within the ranges reported in adults. The apparent sorafenib clearance increased with patient age. Diarrhea, rash, fatigue, and increased ALT/AST were the most common sorafenib-related toxicities. Stable disease for 4 or more cycles was observed in 14 solid tumor patients, and 2 patients with acute myeloid leukemia (AML) and FLT3 internal tandem duplication (FLT3ITD) experienced a decrease in bone marrow blasts to less than 5%. Conclusions: The recommended phase II dose of sorafenib administered every 12 hours continuously for children with solid tumors is 200 mg/m2/dose and 150 mg/m2/dose for children with leukemias. Sorafenib toxicities and distribution in children are similar to adults. The activity of sorafenib in children with AML and FLT3ITD is currently being evaluated, and a phase II study for select solid tumors is ongoing.

AB - Purpose: To determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of sorafenib in children with refractory extracranial solid tumors and evaluate the tolerability of the solid tumor MTD in children with refractory leukemias. Experimental Design: Sorafenib was administered orally every 12 hours for consecutive 28-day cycles. Pharmacokinetics (day 1 and steady-state) and pharmacodynamics were conducted during cycle 1. Results: Of 65 patients enrolled, 60 were eligible. In the solid tumor cohort (n = 49), 4 of 6 patients experienced a DLT [hypertension, pain, rash/urticaria, thrombocytopenia, alanine aminotransferase (ALT)/aspartate aminotransferase (AST)] at the starting dose (150 mg/m2/dose) which resulted in de-escalation to 105 mg/m2/dose. After eligibility criteria modification and dose re-escalation, the MTD was 200 mg/m 2/dose for solid tumors and 150 mg/m2/dose for leukemias. Sorafenib exposure was highly variable between patients but was within the ranges reported in adults. The apparent sorafenib clearance increased with patient age. Diarrhea, rash, fatigue, and increased ALT/AST were the most common sorafenib-related toxicities. Stable disease for 4 or more cycles was observed in 14 solid tumor patients, and 2 patients with acute myeloid leukemia (AML) and FLT3 internal tandem duplication (FLT3ITD) experienced a decrease in bone marrow blasts to less than 5%. Conclusions: The recommended phase II dose of sorafenib administered every 12 hours continuously for children with solid tumors is 200 mg/m2/dose and 150 mg/m2/dose for children with leukemias. Sorafenib toxicities and distribution in children are similar to adults. The activity of sorafenib in children with AML and FLT3ITD is currently being evaluated, and a phase II study for select solid tumors is ongoing.

UR - http://www.scopus.com/inward/record.url?scp=84868543745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868543745&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-3284

DO - 10.1158/1078-0432.CCR-11-3284

M3 - Article

C2 - 22962440

AN - SCOPUS:84868543745

VL - 18

SP - 6011

EP - 6022

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 21

ER -